Mankind Pharma Limited has informed the Exchange regarding Cessation of Mr Pramod Gokhale as Other of the company w.e.f. May 31, 2026.
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Mankind Pharma's Board meeting held on May 19, 2026 approved audited FY2026 standalone results with net profit of ₹713.61 crore, and noted the resignation of Mr. Pramod Gokhale, Global Chief Information Officer (CIO) and Senior Management Personnel, effective close of business on May 31, 2026. The Board also reappointed Mr. Satish Kumar Sharma as Whole-Time Director for another 5-year term from September 23, 2026, approved investment of up to ₹500 crore in subsidiary Mankind Medicare Private Limited, and realigned NCD security cover post redemption of ₹1,250 crore NCDs in April 2026. Three top executive directors (Chairman, Vice Chairman & MD, and CEO) voluntarily waived commission for FY2025-26 to strengthen the company's cash position.
The resignation of the CIO and KMP is a minor change in senior leadership with no immediate material impact on operations. The voluntary commission waiver by top executives signals a shareholder-friendly cash conservation approach. Financial performance showed strong growth with 20% net profit margin for the full year.